Your browser doesn't support javascript.
loading
Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei.
Lam, Anthony R; Bazzi, Khalil; Valle, Sarah J; Morris, David L.
Afiliação
  • Lam AR; Department of Surgery, Peritonectomy Unit, St George Hospital, Kogarah, New South Wales, Australia.
  • Bazzi K; Department of Surgery, Peritonectomy Unit, St George Hospital, Kogarah, New South Wales, Australia.
  • Valle SJ; Department of Surgery, Peritonectomy Unit, St George Hospital, Kogarah, New South Wales, Australia.
  • Morris DL; Department of Surgery, Peritonectomy Unit, St George Hospital, Kogarah, New South Wales, Australia.
Case Rep Oncol ; 14(1): 628-633, 2021.
Article em En | MEDLINE | ID: mdl-33976645
ABSTRACT
Pseudomyxoma peritonei (PMP) is a rare mucinous disease most commonly arising from the appendix. Pleural involvement arising from established PMP is seen in a small number of cases. Combined cytoreductive surgery and hyperthermic intrathoracic chemotherapy is the treatment of choice when managing intra-thoracic PMP. In cases of recurrence, surgical intervention may be technically challenging and carry higher rates of complications, morbidity, and mortality. Bromelain and acetylcysteine (BromAc®) is a novel treatment modality that has demonstrated mucolytic properties. When injected directly into mucinous disease, it facilitates tumour dissolution and allows it to be aspirated. It has recently been tested in the treatment of inoperable peritoneal mucinous disease, with an acceptable safety profile and positive objective response. Here we describe the first two cases of BromAc® administered directly into pleural adenomucinosis, with striking differences in response between the two patients likely due to differences in tumour hardness.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article